



PAYER BULLETIN: ABRYSVO™  **WASHINGTON VACCINE ASSOCIATION**

December 19, 2023

Dear WVA Payer:

On November 1, 2024, you received notice of two new vaccines – **PENBRAYA™** and **ABRYSVO™** – that were expected to be added to the WVA’s [Vaccine Assessment Grid](#). This is an update regarding **ABRYSVO™**. A follow-up notice will be sent once there is more information regarding **PENBRAYA™**.

Effective **January 1, 2024**, **ABRYSVO™** respiratory syncytial virus (RSV) for pregnant persons under the age of 19 will be added to the WVA’s [Vaccine Assessment Grid](#). Providers will bill commercial insurance payers and third-party administrators (TPAs) using the WVA’s dosage-based assessment (DBA) process for patients under the age of 19.

As a payer, you will need to update your adjudication system to include the following CPT code, NDC code, and WVA assessment amount to accurately reimburse the WVA.

Update your fee schedules!

NAME	CPT CODE	NDC CODE / PACKAGING	WVA ASSESSMENT AMOUNT
ABRYSVO™	90678	00069-0344-01 (1 Pack - Single Dose Vial)	\$265.50

For more information regarding the DBA process, please see the [WVA Health Insurer and TPA Compliance Guide](#), wavaccine.org, or compliance@wavaccine.org.

Best regards,

Julia Walter Zell

Julia Walter Zell, MA, Esq., Executive Director